Adenoviral-mediated gene therapy for cardiovascular conditions
National Heart, Lung & Blood Institute is seeking capability statements from parties interested in entering into a Cooperative Research & Development Agreement to develop adenoviral-mediated gene therapy approaches to treating two conditions: restenosis after angioplasty and stimulation of collateral formation in the myocardium. Capability statements are due on or before June 16, according to May 17 Federal Register and should be submitted to Mary Jude Jacobs, NHLBI, 9000 Rockville Pike, Building 31, Room 5A48, Bethesda, Md. 20892
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth